Roche Holdings Ltd ADR (RHHBY)

$57.11 -0.59 (-1.02%)
Market Cap 367.58B
Revenue (ttm) 76.45B
Net Income (ttm) 15.54B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 18.12
Profit Margin 20.33%
Debt to Equity Ratio 1.00
Volume 3,509,200
Avg Vol 2,766,894
Day's Range N/A - N/A
Shares Out 6.37B
Stochastic %K 76%
Beta 0.44
Analysts Sell
Price Target $52.72

Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer,...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 41 61 688 88 80
Fax: 41 61 691 00 14
Address:
Grenzacherstrasse 124, Basel, Switzerland
Jhoooon
Jhoooon Jun. 4 at 10:32 AM
$BMEA Great! Thanks for sharing! Confirming the LLY news from CNBC, the M&A frenzy is officially here. $NVO, $RHHBY, $NVS , $PFE AND many others are all looking to diversify beyond injectable peptides. Biomea is the most disruptive play in the space with its oral covalent menin inhibitor. They aren't just managing symptoms; they are targeting the root cause of diabetes. The fact that $BMEA would still be valued under $1B after a 10x move is absurd. With the current 'arms race' in obesity and diabetes, many do not expect a technology this validated to remain independent much longer. Strategic interest is peaking. In just the last month, Biomea has secured partnerships with 5 of the world's most prestigious diabetes research centers—including Joslin Diabetes Center, Barbara Davis Center, and the University of Leicester. This level of institutional validation in such a short window is unprecedented.
0 · Reply
Tom2772
Tom2772 Jun. 4 at 7:17 AM
$OTLK $PFE $RHHBY $RGBP https://ir.outlooktherapeutics.com/static-files/73f315de-4288-48b2-aba8-4d1fccbad7b4 Details ⬆️⬆️⬆️
0 · Reply
biotech
biotech Jun. 3 at 10:36 AM
BARRONS calling out $SGMO getting Alzheimer’s Drugs Into the Brain Is Hard. Now There’s a New Trick. To get gene therapies into cells both $VYGR and $SGMO are developing capsids that first open blood-brain portals, then deliver genetic cargoes to brain cells Sangamo is developing gene therapies in collaborations with $LLY Lilly, Astrellas (they mean Astellas) , and Roche. $RHHBY https://www.barrons.com/articles/alzheimers-drugs-brain-biotech-a26d24d8
0 · Reply
GreenEnergy7B
GreenEnergy7B Jun. 2 at 8:30 PM
$ALT "Weight-loss drugs can cut breast cancer risk by up to 30%, studies suggest" "The first study, a retrospective analysis of 110,000 women aged between 45 and 80, found those who took GLP-1 medications were 30% less likely to develop breast cancer than those who did not." https://www.theguardian.com/science/2026/jun/02/weight-loss-drugs-cut-cancer-risk-studies $RHHBY $ABBV $NVS $LLY
2 · Reply
GreenEnergy7B
GreenEnergy7B Jun. 2 at 8:29 PM
$ALT "Weight-loss drugs can cut breast cancer risk by up to 30%, studies suggest" "The first study, a retrospective analysis of 110,000 women aged between 45 and 80, found those who took GLP-1 medications were 30% less likely to develop breast cancer than those who did not." https://www.theguardian.com/science/2026/jun/02/weight-loss-drugs-cut-cancer-risk-studies $RHHBY $ABBV $NVS $LLY
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 2 at 4:39 PM
$SLS $GLSI it took 4.5 Months from the 72nd to 80th Event or 1 event every 3 weeks. Its now been a full 3 weeks since the 78th Event May 11. -- Likely Now at 79. -- Be Holding as many as you can when the 80th Event is Announced. That PR is going to Move SLS up to $20 / $3.8B in Market Value, and Climbing - as the Market Begins to digest GPS true value. - A Revolutionary Immunotherapy that will treat 40,000 AML Remission patients each year - with an adinfinite dosing compounding Revenue. - $28B Total Addressable Market. And Gps will set records for patient uptake rates, Safe, easy to administer, 2X - 4X Survival Advantage. Ps $ABBV $RHHBY $BMY Own VEN Aza - VEN - Aza Failed the VIALE-M CR1 Remission Maintenance Phase 3 Trial. they Know Ven Aza Failed the Control Arm Patients in the SLS CR2 Remission Maintenance Trial - and that it is GPS doing what its done in all prior trials, Prevent Relapse and Extend Survival, including in 2 Phase 2 Trials for CR maintenance.
1 · Reply
LabPsycho
LabPsycho Jun. 2 at 2:07 PM
$MAIA @telomerase Here is the biochemical basis for me proposing the creation of a new entity using $MAIA drug THIO with Regeneron $REGN or Roche $RHHBY Anti-PD-L1 antibody (ADC -THIO drug conjugate). The cleavage of disulfide bonds in the Tumor Micro Environment (TME) can be driven by reduction-oxidation reactions. Disulfide bonds are cleaved by endogenous reducing agents, most notably glutathione (GSH). The TME is characteristically hypoxic and highly reductive. It is significantly enriched in intracellular reducing agents like GSH, which are often present at much higher concentrations inside cancer cells compared to normal tissues. Therapeutic Application: Because of this unique reductive characteristic, tumors effectively break down disulfide linkages. This is used in oncology to design "reduction-responsive" smart drug delivery systems (e.g., targeted antibody-[MAIA’s Thio] conjugate) that only release their toxic payloads when they reach the reductive environment of the tumor.
1 · Reply
clan
clan Jun. 1 at 1:43 PM
$MNKD For the good of all Mannkind, on Wednesday, the CEO speaks at the Jefferies Global Health Care conference. Afrezza c/b Blockbuster Nintedanib DPI t/b Blockbuster Tyvaso DPI is Blockbuster Ralinepag DPI t/b Blockbuster Furoscix AutoInjector t/b Blockbuster $RHHVF $RHHBY $IBB take notice.
0 · Reply
dogDazeSummer
dogDazeSummer May. 30 at 3:14 PM
$IFRX Late Friday Oppenheimer upgrade: “We are updating our IFRX model to reflect izicopan's pivot to ANCA-associated vasculitis (AAV) as the lead indication, alongside the recently closed $150M equity raise that extends runway through 2029E, increasing our price target to $9 from $5. The PT increase is primarily driven by a shift in underlying value drivers——izicopan's HS has been deprioritized to a partnered, royalty-based opportunity, while AAV emerges as the new lead value driver representing a meaningfully larger commercial opportunity (~$3.0B combined US + EU peak sales in 2040E at 30%E (PoS). With financing risk materially reduced and a defined development roadmap in place, we believe IFRX offers asymmetric exposure to the C5aR class ahead of Capital Markets Day this summer. $AMGN $BIIB $RHHBY $PFE The 2029 runway opens M&A windows and we are now an odds on favorite w AAV given multiple Avacopan unforgivable “errors”. FDA simply can’t look the other way.
0 · Reply
amessagefromtheodd
amessagefromtheodd May. 30 at 11:24 AM
$SLS When / if SELLAS delivers strong AML data, the market will have its proof. At that point, the debate shifts from “does it work?” to “how big can the AML opportunity get, and who wants to own it?” $MRK $ABBV $PFE $RHHBY
1 · Reply
Latest News on RHHBY
No data available.
Jhoooon
Jhoooon Jun. 4 at 10:32 AM
$BMEA Great! Thanks for sharing! Confirming the LLY news from CNBC, the M&A frenzy is officially here. $NVO, $RHHBY, $NVS , $PFE AND many others are all looking to diversify beyond injectable peptides. Biomea is the most disruptive play in the space with its oral covalent menin inhibitor. They aren't just managing symptoms; they are targeting the root cause of diabetes. The fact that $BMEA would still be valued under $1B after a 10x move is absurd. With the current 'arms race' in obesity and diabetes, many do not expect a technology this validated to remain independent much longer. Strategic interest is peaking. In just the last month, Biomea has secured partnerships with 5 of the world's most prestigious diabetes research centers—including Joslin Diabetes Center, Barbara Davis Center, and the University of Leicester. This level of institutional validation in such a short window is unprecedented.
0 · Reply
Tom2772
Tom2772 Jun. 4 at 7:17 AM
$OTLK $PFE $RHHBY $RGBP https://ir.outlooktherapeutics.com/static-files/73f315de-4288-48b2-aba8-4d1fccbad7b4 Details ⬆️⬆️⬆️
0 · Reply
biotech
biotech Jun. 3 at 10:36 AM
BARRONS calling out $SGMO getting Alzheimer’s Drugs Into the Brain Is Hard. Now There’s a New Trick. To get gene therapies into cells both $VYGR and $SGMO are developing capsids that first open blood-brain portals, then deliver genetic cargoes to brain cells Sangamo is developing gene therapies in collaborations with $LLY Lilly, Astrellas (they mean Astellas) , and Roche. $RHHBY https://www.barrons.com/articles/alzheimers-drugs-brain-biotech-a26d24d8
0 · Reply
GreenEnergy7B
GreenEnergy7B Jun. 2 at 8:30 PM
$ALT "Weight-loss drugs can cut breast cancer risk by up to 30%, studies suggest" "The first study, a retrospective analysis of 110,000 women aged between 45 and 80, found those who took GLP-1 medications were 30% less likely to develop breast cancer than those who did not." https://www.theguardian.com/science/2026/jun/02/weight-loss-drugs-cut-cancer-risk-studies $RHHBY $ABBV $NVS $LLY
2 · Reply
GreenEnergy7B
GreenEnergy7B Jun. 2 at 8:29 PM
$ALT "Weight-loss drugs can cut breast cancer risk by up to 30%, studies suggest" "The first study, a retrospective analysis of 110,000 women aged between 45 and 80, found those who took GLP-1 medications were 30% less likely to develop breast cancer than those who did not." https://www.theguardian.com/science/2026/jun/02/weight-loss-drugs-cut-cancer-risk-studies $RHHBY $ABBV $NVS $LLY
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 2 at 4:39 PM
$SLS $GLSI it took 4.5 Months from the 72nd to 80th Event or 1 event every 3 weeks. Its now been a full 3 weeks since the 78th Event May 11. -- Likely Now at 79. -- Be Holding as many as you can when the 80th Event is Announced. That PR is going to Move SLS up to $20 / $3.8B in Market Value, and Climbing - as the Market Begins to digest GPS true value. - A Revolutionary Immunotherapy that will treat 40,000 AML Remission patients each year - with an adinfinite dosing compounding Revenue. - $28B Total Addressable Market. And Gps will set records for patient uptake rates, Safe, easy to administer, 2X - 4X Survival Advantage. Ps $ABBV $RHHBY $BMY Own VEN Aza - VEN - Aza Failed the VIALE-M CR1 Remission Maintenance Phase 3 Trial. they Know Ven Aza Failed the Control Arm Patients in the SLS CR2 Remission Maintenance Trial - and that it is GPS doing what its done in all prior trials, Prevent Relapse and Extend Survival, including in 2 Phase 2 Trials for CR maintenance.
1 · Reply
LabPsycho
LabPsycho Jun. 2 at 2:07 PM
$MAIA @telomerase Here is the biochemical basis for me proposing the creation of a new entity using $MAIA drug THIO with Regeneron $REGN or Roche $RHHBY Anti-PD-L1 antibody (ADC -THIO drug conjugate). The cleavage of disulfide bonds in the Tumor Micro Environment (TME) can be driven by reduction-oxidation reactions. Disulfide bonds are cleaved by endogenous reducing agents, most notably glutathione (GSH). The TME is characteristically hypoxic and highly reductive. It is significantly enriched in intracellular reducing agents like GSH, which are often present at much higher concentrations inside cancer cells compared to normal tissues. Therapeutic Application: Because of this unique reductive characteristic, tumors effectively break down disulfide linkages. This is used in oncology to design "reduction-responsive" smart drug delivery systems (e.g., targeted antibody-[MAIA’s Thio] conjugate) that only release their toxic payloads when they reach the reductive environment of the tumor.
1 · Reply
clan
clan Jun. 1 at 1:43 PM
$MNKD For the good of all Mannkind, on Wednesday, the CEO speaks at the Jefferies Global Health Care conference. Afrezza c/b Blockbuster Nintedanib DPI t/b Blockbuster Tyvaso DPI is Blockbuster Ralinepag DPI t/b Blockbuster Furoscix AutoInjector t/b Blockbuster $RHHVF $RHHBY $IBB take notice.
0 · Reply
dogDazeSummer
dogDazeSummer May. 30 at 3:14 PM
$IFRX Late Friday Oppenheimer upgrade: “We are updating our IFRX model to reflect izicopan's pivot to ANCA-associated vasculitis (AAV) as the lead indication, alongside the recently closed $150M equity raise that extends runway through 2029E, increasing our price target to $9 from $5. The PT increase is primarily driven by a shift in underlying value drivers——izicopan's HS has been deprioritized to a partnered, royalty-based opportunity, while AAV emerges as the new lead value driver representing a meaningfully larger commercial opportunity (~$3.0B combined US + EU peak sales in 2040E at 30%E (PoS). With financing risk materially reduced and a defined development roadmap in place, we believe IFRX offers asymmetric exposure to the C5aR class ahead of Capital Markets Day this summer. $AMGN $BIIB $RHHBY $PFE The 2029 runway opens M&A windows and we are now an odds on favorite w AAV given multiple Avacopan unforgivable “errors”. FDA simply can’t look the other way.
0 · Reply
amessagefromtheodd
amessagefromtheodd May. 30 at 11:24 AM
$SLS When / if SELLAS delivers strong AML data, the market will have its proof. At that point, the debate shifts from “does it work?” to “how big can the AML opportunity get, and who wants to own it?” $MRK $ABBV $PFE $RHHBY
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 29 at 4:02 PM
$SLS VIALE-M the $ABBV Phase 3 for AML First Remission Maintenance (CR1) - Failed - 7 Different Dosing Regimes - were Tried, High Intensity Low Intensity, IV Sub Q and all ORAL ... ALL too Toxic. - Results are Public https://clinicaltrials.gov/study/NCT04102020?term=viale-M&viewType=Card&rank=1&tab=study#publications the SAP went through 7 iterations ABBV $RHHBY $BMY -- these Big Pharma - who Own Aza Ven, and Paid for the P3 trials - KNOW RIGHT NOW - it is GPS Doing what its done in ALL PRIOR Trials - Prevent Relapse and Extend Survival.
0 · Reply
BTECHINV
BTECHINV May. 27 at 8:30 PM
$ALT Scientifically, Pemvi has now achieved... + p<0.001 qFibrosis ≥ 1+ stage improvement at 24W (Femtosecond Laser Photonics Fluorescence Microscopy) + p<0.0001 MASH RESOLUTION at 24W (via trad Pathology) + p<0.0001 Pathological Fibrotic Tissue Area reduction at 30%+ level (via Path AI Liver Explore/Roche $RHHBY) + United States FDA Breakthrough Therapy Designation (MASH, January 2026) + Extensive, broad-based, statistically significant Liver NIT KPI's + Stat. Sig. hq Weight Loss + etc. The single most important step at this juncture ALTIMMUNE management can do for all shareholders (non-institutional individual retail and institutional) is to accelerate Pemvi into global MASH registrational trials. BP's and their investment bankers will have to make a decision at some juncture, Pemvi has the potential to become a strong and disruptive Liver & Cardiometabolic drug franchise in my view (assuming successful P3 of course). Disclosure: Not medical / not investment advice.
2 · Reply
GreenEnergy7B
GreenEnergy7B May. 27 at 8:00 PM
$ALT Approx 10% better placebo adj, 3x faster, and 0 disc, better Tolerability profile vs Wegovy. 1.2mg dose looks very attractive $LLY $RHHBY $SNY $ABBV
1 · Reply
Tom2772
Tom2772 May. 26 at 6:05 PM
$OTLK $NVS $RHHBY Time to jump into money!
0 · Reply
Tom2772
Tom2772 May. 26 at 6:00 PM
$OTLK $NVS $RHHBY https://ir.outlooktherapeutics.com/news-releases/news-release-details/outlook-therapeutics-wins-appeal-following-formal-dispute Nothing is over!
0 · Reply
Aldinho_lbk
Aldinho_lbk May. 26 at 4:15 PM
$OTLK people taking a sip on speculative take over, with Roche $RHHBY as potential candidate. Allow me to differ. ALCON $ALC and Baush Lamb $BLCO are more suitable partners here in the USA, even for a M&A...
1 · Reply
grampslol
grampslol May. 26 at 10:56 AM
Poor pennyland $MNKD pumper @clan ...smh...deluding himself as he tries to deceive the naive about technosphere when he knows afrezza dpi inhaled insulin approved in 2014 is a epic flop ... $MRK $RHHBY
1 · Reply
clan
clan May. 26 at 10:43 AM
$RHHBY $REGN $MRK The next generation of INHALABLE therapuetics will be acquired by one of these companies. Not IF, but WHEN. For the good of all Mannkind [ and $MNKD ]. #technosphere
0 · Reply
scotttrader213
scotttrader213 May. 22 at 3:51 PM
$RHHBY moving towards 55.00
0 · Reply
DidYouReadThis
DidYouReadThis May. 22 at 2:49 PM
$OTLK $OTLK $OTLK If one potential P/E ratio maximum might be estimated at 19.63 (an approximate average of the P/Es of $NVS, $REGN, $RHHBY ) what’s a realistic share price ceiling for $OTLK in 10 years? Please share your math. Thank you!
0 · Reply
kcresskill12345
kcresskill12345 May. 21 at 6:40 PM
$SLS $RHHBY $MRK $XBI SLS is finally correcting after that absurd run‑up. Looks like the market makers are finally doing what they’re supposed to do. Two rules never fail: don’t fight the fundamentals, and don’t fight the market makers. First stop is around $5.80, then $4.31, and eventually this drifts all the way back to its real home at $1. The unwind has officially begun.
2 · Reply
BioRich
BioRich May. 21 at 4:33 PM
$SLS Thanks to Bulls for helping re-alive these realities... $SLS's history of FAILURE... 1) Genentech/Roche ($RHHBY ) previously collaborated on NeuVax (NPS) and ended the partnership after the Phase 3 PRESENT trial failed — this is documented in Galena/SLS SEC filings. 2) Merck ($MRK )also supplied Keytruda for a GPS combo study, but after reviewing the early data, they didn’t extend or partner (confirmed in SELLAS 10‑Ks). 3) $SLS CEO Stooge's last Phase 3 trial for the once can't miss prospect BioVaxID was rejected by the FDA and required to run an additional Phase 3 after trial modifications (under Stooge's direction) made results unapprovable. Don't forget, based on the trial modifications to dosing regimens, I firmly believe GPS will have the same fate of being rejected by the Agency, even if they hit statistical significance (which Stooge's last magic trick did). Special thanks @kcresskill12345 @AL_Bourla $XBI
0 · Reply